Genome Editing in Drug Discovery

GENOME EDITING IN DRUG DISCOVERY

A practical guide for researchers and professionals applying genome editing techniques to drug discovery

In Genome Editing in Drug Discovery, a team of distinguished biologists delivers a comprehensive exploration of genome editing in the drug discovery process, with coverage of the technology’s history, current issues and techniques, and future perspectives and research directions. The book discusses techniques for disease modeling, target identification with CRISPR, safety studies, therapeutic editing, and intellectual property issues.

The safety and efficacy of drugs and new target discovery, as well as next-generation therapeutics are also presented.

Offering practical suggestions for practitioners and academicians involved in drug discovery, Genome Editing in Drug Discovery is a fulsome treatment of a technology that has become part of nearly every early step in the drug discovery pipeline. Selected contributions also include:

• A thorough introduction to the applications of CRISPRi and CRISPRa in drug discovery
• Comprehensive explorations of genome-editing applications in stem cell engineering and regenerative medicine
• Practical discussions of the safety aspects of genome editing with respect to immunogenicity and the specificity of CRISPR-Cas9 gene editing
• In-depth examinations of critical socio-economic and bioethical challenges in the CRISPR-Cas9 patent landscape

Perfect for academic researchers and professionals in the biotech and pharmaceutical industries, Genome Editing in Drug Discovery will also earn a place in the libraries of medicinal chemists, biochemists, and molecular biologists.

Marcello Maresca, PhD, is a Senior Director in the Discovery Sciences Department at AstraZeneca. He obtained his doctorate in Molecular Biology from the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany.

Sumit Deswal, PhD, is a Senior Scientist with the Genome Engineering Team at AstraZeneca R&D in Sweden. He obtained his doctorate in Immunology from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany.